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Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is characterized
by chromosomal rearrangements that activate several onco-
genes, such as TAL1, LMO2, HOXA, TLX1 and TLX3, which
predominantly occur in a mutually exclusive pattern. In our
previous study, we used a supervised gene-expression profiling
approach to cluster T-ALL patients with these chromosomal
aberrations.1 Patients with HOXA, TLX1 and TLX3 abnormali-
ties formed 3 separate T-ALL clusters. Patients with TAL1
and/or LMO2 rearrangements formed a single, fourth TAL -
LMO cluster, explained by the fact that TAL1 and LMO2 parti -
cipate in the same transcription complex and affect similar
downstream pathways. Co-clustering of 45 additional patients
who lack TAL1, LMO2, HOXA, TLX1 or TLX3 aberrations, led
to the identification of 2 additional T-ALL genetic subgroups
that are characterized by NKX2-1/NKX2-2 or MEF2C-activat-
ing rearrangements.1 The MEF2C-deregulated subgroup over-
lapped with the early thymic progenitor ALL (ETP-ALL) sub-
group, as previously described by Dario Campana and co-
workers.2 Nineteen of these 45 patient samples strongly co-
clustered with TAL1- or LMO2-rearranged patients in super-
vised and unsupervised cluster analyses, pointing to a common
pathogenic mechanism. These 19 cases were denoted as TALL-
MO-likes, and we hypothesized that these patients might har-
bor rearrangements involving factors homologous to TAL1 or
LMO2, or factors that participate in the TAL/LMO transcrip-
tion complex. This hypothesis was confirmed when we iden-
tified translocations that involved LMO3,3 LMO1 or TAL2 in 3
of these TALLMO-like patients.4 A fourth patient had double
translocations affecting TAL2 and LMO1 oncogenes.4 To iden-
tify aberrations in the remaining 15 TALLMO-like patients, we
screened for T-cell receptor driven translocations for which the
translocation partner was unknown.
Design and Methods
Patient material
Viably frozen diagnostic bone marrow or peripheral blood
samples from 117 pediatric T-ALL patients was used.1,4
Clinical and immunophenotypic data were provided by the
German Co-operative study group for childhood Acute
Lymphoblastic Leukemia (COALL) and the Dutch Childhood
Oncology Group (DCOG). The patients’ parents or their legal
guardians provided informed consent to use leftover material
for research purposes in accordance with the declaration of
Helsinki, and the study was approved by the ethical commit-
tee of the Erasmus Medical Center. Leukemic cells were iso-
lated and enriched from these samples as previously
described.5 All resulting samples contained 90% or more
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Translocation of the LYL1 oncogene are rare in T-cell acute
lymphoblastic leukemia, whereas the homologous TAL1
gene is rearranged in approximately 20% of patients.
Previous gene-expression studies have identified an imma-
ture T-cell acute lymphoblastic leukemia subgroup with high
LYL1 expression in the absence of chromosomal aberrations.
Molecular characterization of a t(7;19)(q34;p13) in a pediatric
T-cell acute lymphoblastic leukemia patient led to the identi-
fication of a translocation between the TRB@ and LYL1 loci.
Similar to incidental T-cell acute lymphoblastic leukemia
cases with synergistic, double translocations affecting
TAL1/2 and LMO1/2 oncogenes, this LYL1-translocated
patient also had an LMO2 rearrangement pointing to onco-
genic cooperation between LYL1 and LMO2. In hierarchical
cluster analyses based on gene-expression data, this sample
consistently clustered along with cases having TAL1 or
LMO2 rearrangements. Therefore, LYL1-rearranged cases are
not necessarily associated with immature T-cell develop-
ment, despite high LYL1 levels, but elicit a TALLMO expres-
sion signature.
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ABSTRACT
leukemic cells, as determined morphologically by May-
Grünwald-Giemsa-stained cytospins (Merck, Darmstadt,
Germany). Cytospin slide preparation and DNA and RNA
extraction were performed as previously described.5
Fluorescent in situ hybridization (FISH)
FISH analysis was performed on cytospin slides using
the TCRalpha/delta and TCRbeta split signal probes
according to the manufacturer’s protocol (DAKO,
Glostrup, Denmark). Split signal FISH on the LYL1 locus
was performed using the following BAC clones as previ-
ously described:6 RP11-352L7, RP11-356L15.
Ligation mediated PCR (LM-PCR) and real-time
quantitative PCR (RQ-PCR)
LM-PCR for TRB@ breakpoint hotspots (TRB@D1 and
TRB@D2), and RQ-PCR for LYL1 were performed as pre-
viously described.5,7,8 For LM-PCR, briefly, genomic DNA
was digested with either one of four different restriction
enzymes (PvuII, HincII, StuI, DraI) and ligated to adapters.
Adaptor primers were then used in combination with
TRB@ loci specific primers to amplify the breakpoint
region in two PCR rounds. For the detection of the recip-
rocal LYL1-TRB@ breakpoint, the following specific
primers located near LYL1 were used. First: 5’-CGG GCT
GGA GGA GAG AAG-3’, nested: 5’-GTG GCT GAC
GAC GTG TAA TTT-3’.
Results and Discussion
A FISH strategy was performed to identify novel TRB@-
or TRAD@-driven oncogenic rearrangements in 15 TAL -
LMO-like patients. These 15 cases strongly clustered in
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Figure 1. Unsupervised and supervised hierarchical clustering of 117 pediatric T-ALL samples and 7 normal bone marrow samples. (A)
Unsupervised hierarchical clustering of 117 pediatric T-ALL samples and 7 normal bone marrow samples (horizontal axis), according to
microarray gene-expression (genes on vertical axis, gene names not shown).1 Red corresponds to high expression, blue to low expression.
CD surface markers are shown as present (>25%, “+”), absent (<25% “-“) or not performed (white). Complete immunophenotype for #704:
CD1-, CD2+, CD3-, CD4+, CD5-, CD7+, CD8+, cytoplasmatic CD3+, CD33-, CD14-, CD34-, CD71+, HLA_DR-, TDT+. Cytogentic abnormalities
are shown as follows. T: SIL-TAL deletion or TAL1 translocation; L: LMO2 translocation/deletion; 1: TLX1 translocation; 3: TLX3 translocation;
B: normal bone marrow; N: NKX2-1 translocation/inversion/duplication; M: MYB translocation; H: HOXA activating abberation (CALM-AF10,
SET-NUP, HOXA inversion). Patient #704 is highlighted by a blue box. (B) Principal component analysis of supervised analyses of gene-
expression data of 117 pediatric T-ALL samples.1 The position of the yellow dots representing LMO1, TAL2, LMO3, TAL2/LMO1 rearranged
cases and sample #704 (LYL1/LMO2) are indicated by arrows. 
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hierarchical cluster analyses with T-ALL cases having
TAL1/2 and/or LMO1/2/3 rearrangements (Figure 1A and
B). One sample (#704), from a 7-year old male patient,
showed a TRB@ split signal pointing to a translocation
that had not been revealed by karyotypic analysis
(47,XY,+8[6]/46,XY[7]).
We then performed ligation-mediated PCR (LM-PCR)
from two TRB@ translocation hotspots (TRB@D1 and
TRB@D2) on DNA from this patient and identified a
translocation between TRB@D1 and the last intron of the
nuclear factor I/X (NFIX) gene for the derivative chromo-
some 7 (der(7)) (Figure 2A and B). The reciprocal break-
point of the derivative chromosome 19 couples part of the
last intron of the NFIX gene to an area between TRB@J1
and TRB@J2 (der(19); Figure 2A). The Lymphoid leukemia 1
(LYL1) gene is located 240bp centromeric of NFIX and is,
therefore, placed under the influence of the TRB@
enhancer as a consequence of this translocation (Figure
2A). NFIXwas not expressed in any of our patient samples
based on microarray data (raw fluorescent intensities<50,
5 probesets; data not shown) indicating that changes in
NFIX are not contributing to leukemogenesis. Positioning
of the LYL1 gene under the influence of the TRB@
enhancer may explain the relatively high expression level
of LYL1 in this patient (Figure 2C). FISH analysis of the
LYL1 locus on the remaining 14 TALLMO-like patients
revealed no additional LYL1 rearrangements.
Various research groups including ours have reported
that LYL1 and LMO2 are highly expressed in T-ALL
patients with an immature immunophenotype,10-12
despite the fact that LMO2 rearrangements that are also
associated with ectopic LMO2 expression are exclusively
associated with the TALLMO subgroup which has a
more advanced immunophenotype.1,13 In another study,2
immature T-ALL cases were described with an early
thymic progenitor expression profile that was associated
with poor prognosis, and were denoted as ETP-ALL
cases. Based on combined expression profiling and
molecular-cytogenetic analyses, we recently identified an
immature T-ALL subset that was predominantly charac-
terized by rearrangements that activate the MEF2C
oncogene.1 This subset could also be predicted by the
ETP-ALL profile. For these immature, ETP-ALL cases,
MEF2C has been shown to directly activate expression of
LYL1, LMO2 and HHEX1 that may explain the high LYL1
expression in immature T-ALL cases. So far, we and oth-
ers have been unable to reveal LYL1 rearrangements in
these immature, ETP-ALL cases.1,2,10 In line with this, the
single reported T-ALL case with an LYL1 translocation
had a mature (CD3+, CD1-, CD4+, CD8+ and CD34-)
immunophenotype.14
LYL1 is a basic helix-loop-helix (bHLH) transcription
factor that shows 82% amino acid homology in the bHLH
domain with TAL1.15 TAL1 and LYL1 also show overlap-
ping expression patterns in hematopoietic development16
and in some pathways they can exert identical functions.17
The strong co-clustering of this patient sample (#704)
along with TAL1-rearranged T-ALL cases indicates that
LYL1 rearrangements elicit a similar expression profile as
TAL1 rearrangements during T-cell oncogenesis.
Using array-CGH, we further identified a small
del(11)(p12p13) near the LMO2 locus in this patient #70413
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Figure 2. Schematic overview of LYL1-TRB@ translocation and breakpoint sequences. (A) Schematic overview of breakpoint loci on germline
chromosomes 19 and 7, and the der(19) and der(7). Arrows indicate approximate breakpoint locations; *: approximate breakpoint of pre-
viously described LYL1 translocation;9 c: centromeric side; t: telomeric side of chromosal region. (B) Reciprocal breakpoint sequences of the
t(7;19)(q34;p13). In caps sequences corresponding to chromosomal regions as described below, in non-caps; randomly inserted nucleotides.
LYL1 (C) and LMO2 (D) expression according to VSN normalized array data in the four subgroups as shown in Figure 1A. 
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(data not shown), accompanied by ectopic LMO2 expres-
sion (Figure 2D). No copy number changes were found at
the TAL1 locus. LMO2 rearrangements (translocations or
del(11)(p12p13)) occur in approximately 9% of pediatric
T-ALL13 and have been exclusively associated with the
TALLMO subgroup.1,13 The identification of an LYL1
translocation, as well as an LMO2 rearrangement in this
TALLMO-like patient implies that LYL1 and LMO2 syner-
gize in T-cell oncogenesis. Other incidental cases harbor
TAL1/2 as well as LMO1/2 aberrations,4 and 2 additional
cases out of 55 TALLMO patients (including the TALLMO-
like patients) as present in our T-ALL cohort (n=117) had
combined rearrangements of TAL and LMO family mem-
bers: one case had an SIL-TAL1 deletion and the LMO2-
activating del(11)(p12p13), and one had a TAL2/TRB@
translocation in combination with an LMO1/TRAD@
translocation.4 This points to strong synergistic effects
between these oncogenic family members in line with
their participation in similar transcriptional complexes.18-20
Lmo1/Lmo2 and Tal1 have also been shown to synergize
to T-cell leukemogenesis in mice studies.18,21-23
To conclude, we suggest that LYL1 rearranged cases are
not part of the immature, ETP-ALL subgroup, but belong
to the TALLMO subgroup. LYL1 translocations fulfill a
TAL1-like role that can synergize with LMO2 aberrations
in T-cell oncogenesis.
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